Diagnostics
A rare thing in healthcare: negative working capital. Patients pay upfront, inventory is light — so the constraint is never cash, it is demand density. Which is also why the category has low entry barriers and relentless price competition.
Referral density is the moat, turnaround time is the product, and machine utilisation is the margin. Judge a lab on the mix between commoditised pathology and defensible high-end imaging and molecular work.
Three provider types, and mixes that decide everything.
Corporate chains
Large branded laboratory networks with hub-and-spoke reach and national referral relationships.
Standalone labs
Independent local operators — the fragmented majority, competing largely on price.
Hospital in-house
Captive labs inside hospitals. A structural competitor for exactly the work a chain wants.
The mixes that matter
- Pathology vs radiologyDifferent capital intensity entirely. Pathology is asset-light and commoditised; radiology carries scanner capex and better defensibility.
- Routine vs specialisedRoutine tests are price-taken. Molecular, histopathology and PET/CT carry premium pricing and real barriers.
- B2C vs B2B vs PPPB2C is the best-margin, upfront-paying channel. B2B and PPP mean negotiated lower rates and high receivables.
- GeographyMetro versus tier 1/2 changes both realisation and utilisation, particularly for imaging.
The comparable set is not homogeneous
- Imaging-heavy chains — scanner economics dominate
- PPP-contract operators — different pricing regime entirely
- Pathology-led chains — less comparable on imaging
- High-volume, low-price pathology players — a different price point again
Comparing a PPP imaging operator to a B2C pathology chain on revenue multiples is the standard error in this sector.
Negative working capital, hub-and-spoke assets.
The cash cycle is genuinely attractive. Labs are not working-capital intensive: customers pay upfront and inventory requirements are modest. B2C revenue therefore carries negative working capital — growth funds itself. The exception is B2B and PPP, where negotiated rates come attached to high receivables.
The asset model is hub-and-spoke. A few large central labs process the complex work; many smaller spokes and collection points feed them. That structure concentrates expensive equipment where volume justifies it, and is why a new spoke's ramp — what share of mature volumes it hits at month 3, 6 and 12 — is the key expansion metric.
Integration creates bargaining power. An integrated lab can offer better test packages, which improves both profitability and retention — the one-stop-shop effect. Bundling is one of the few genuine pricing levers in a commoditised category.
Imaging capital
- New scanner₹1.5–3.5 crore (1.5T, 16-channel MRI class).
- Refurbished₹0.8–2.8 crore — materially changes the payback maths.
- The metricScans per machine per day, and machine uptime — the proportion of time the unit is available and working.
- Modality economicsCT, MRI and PET each carry their own EBITDA profile. Track per-modality, not blended.
Seasonality: Q2 and Q4 are typically the strongest quarters.
Referrals, turnaround, and test mix.
Active referral density
Doctors who actually referred in the last 30 or 90 days — not the cumulative empanelled list. This is the demand engine, and a fall of more than 10% quarter-on-quarter is an early warning.
Turnaround time
Time from sample collection to report is the product experience. Consistent TAT earns clinician trust and supports a genuine price premium in a category that otherwise has none.
High-end test mix
Molecular, histopathology, PET, CT and MRI carry pricing power that routine panels do not. The share of revenue from specialised work is the defensibility metric.
What to answer before underwriting.
- →Revenue mix. Pathology versus radiology; routine versus specialised versus wellness; B2C versus B2B versus PPP versus aggregators; and by geography.
- →Active referring doctors. How many referred in the last 30 and 90 days, and is that number growing? Cumulative empanelment is a vanity metric.
- →Imaging utilisation. Scans per machine per day and machine uptime, split metro versus tier 1/2. How is utilisation actually measured?
- →Per-modality economics. EBITDA by CT, MRI and PET — blended imaging margin hides underperforming assets.
- →New-centre ramp. What share of mature volumes does a new spoke reach at month 3, 6 and 12? Hub and spoke breakeven and payback.
- →Turnaround time. Actual TAT by test category, and whether it supports a price premium.
- →Corporate accounts. Share of revenue, and how sticky those HR and procurement relationships genuinely are.
- →PPP and B2B terms. Negotiated rate levels and receivable days — the offset to the sector's otherwise negative working capital.
- →Aggregator exposure. Any business from online diagnostic aggregators, and at what margin.
- →Home collection. Share of tests, growth rate, and the cost-to-serve on that channel.
- →Accreditation. NABL status where it matters — CGHS work and government hospital contracts require it.
- →Capex plan. New versus refurbished scanner strategy, and what that does to payback and uptime risk.
What to monitor, quarter by quarter.
| KPI | Calculation / source | Benchmark or read-through |
|---|---|---|
| Active referring doctors | Referred in last 30 / 90 days | A fall >10% QoQ is the sector's clearest early warning |
| Total tests performed | Volume, YoY | The base demand measure; split routine vs specialised |
| Tests per footfall | Total tests ÷ footfalls | Bundling and package effectiveness |
| Revenue per test | Revenue ÷ tests | Falling revenue per test with rising volume = price competition biting |
| ARPP | Revenue ÷ patients | Around ₹555 as a reference point; track the blended price index |
| High-end mix % | Molecular, histopath, PET, CT, MRI ÷ revenue | The defensibility metric against commoditised panels |
| Wellness mix % | Preventive and wellness ÷ revenue | Growing, B2C, and typically upfront-paying |
| Scans per machine per day | By modality | The imaging utilisation number that drives per-modality EBITDA |
| Machine uptime | Available working hours ÷ total | Downtime on a ₹1.5–3.5 cr asset is expensive idle capital |
| Per-modality EBITDA | By CT / MRI / PET | Blended imaging margin conceals weak assets |
| Turnaround time | Collection to report, by category | The trust metric; supports premium pricing |
| Home collection share | Tests via home collection ÷ total | Growth channel; check cost-to-serve, not just volume |
| Channel mix | B2C / B2B / PPP / aggregator | B2C is negative working capital; B2B and PPP reverse that |
| Receivable days | Debtors ÷ revenue × 365 | Should be very low; a rise means B2B/PPP mix is growing |
| New-centre ramp | % of mature volumes at M3 / M6 / M12 | The expansion quality metric |
| Hub and spoke payback | Months to breakeven per unit | Determines whether network expansion creates or consumes value |
How the thesis breaks.
- !Low entry barriers. The core service is commoditised, NABL is not universally mandatory, and competition is intense. Pricing power must be demonstrated, never assumed.
- !Referral erosion. Active referring doctors falling more than 10% quarter-on-quarter precedes revenue decline and is easy to miss behind headline volumes.
- !Price competition. Rising test volumes alongside falling revenue per test is the signature of a share war, not of growth.
- !Hospital in-house labs. Captive hospital labs take exactly the high-value work a chain wants, and the hospital controls the referral.
- !PPP and B2B drag. Negotiated lower rates plus high receivables reverse the sector's best structural feature.
- !Imaging underutilisation. A ₹1.5–3.5 crore scanner running below capacity destroys the return regardless of headline growth.
- !Aggregator margin capture. Online diagnostic aggregators bring volume while taking the customer relationship and part of the margin.
The figures, and where they stand.
| Metric | Value | Note | Basis |
|---|---|---|---|
| ARPP reference | ~₹555 | Average revenue/realisation per patient | Research note |
| New scanner capex | ₹1.5–3.5 cr | 1.5T, 16-channel MRI class | Research note |
| Refurbished scanner | ₹0.8–2.8 cr | Materially changes payback | Research note |
| Referral warning threshold | >10% QoQ fall | In active referring doctors | Rule of thumb |
| Working capital | Negative (B2C) | Upfront payment, light inventory | Structural |
| Best quarters | Q2 and Q4 | Seasonality of demand | Seasonal |
| NABL requirement | CGHS + govt only | Not mandatory for all labs — a low barrier | Regulatory |